Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model

Urology

Volumn 49, Issue 5, 1997, Pages 795-801

  Geldof, A A ^a   Van Den Tillaar, P L M ^a   Newling, D W W ^a   Teule, G J J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RHENIUM 186;

ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; LUMBAR SPINE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SPINE METASTASIS; TREATMENT OUTCOME;

ANIMALS; ETIDRONIC ACID; LUMBAR VERTEBRAE; MALE; PROSTATIC NEOPLASMS; RADIOISOTOPES; RATS; RHENIUM; SPINAL NEOPLASMS; SURVIVAL RATE;

EID: 0030984573     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00576-6     Document Type: Article

References (17)

1. Bland JH: Infections and tumors, in Bland JH (Ed): Disorders of the Cervical Spine: Diagnosis and Medical Management, 2nd ed. Philadelphia, Saunders, 1994, pp 221-253.
2. Mertens WC, Reid RH, Porter AT, and Powe JE: Recent advances in radionuclide therapy of bone metastases. Nucl Med Ann 1992: 69-89, 1992.
3. Holmes RA: Radiopharmaceuticals in clinical trials. Semin Oncol 20(suppl 2): 22-26, 1993.
4. Robinson RG, Preston DF, Baxter KG, Dusing RW, and Spicer JA: Clinical experience with strontium-89 in prostatic and breast cancer patients. Semin Oncol 20(suppl 2): 44-48, 1993.
5. Robinson RG, Preston DF, Schiefelbein M, and Baxter KG: Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 274: 420-424, 1995.
6. Maxon HR, Schroder LE, Thomas SR, Hertzberg VS, Deutsch EA, Scher HI, Samaratunga RC, Libson KF, Williams CC, Moulton JS, et al: Re-186(Sn)HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormonal-resistant prostate cancer. Radiology 176: 155-159, 1990.
7. de Klerk JMH, van Dijk A, van het Schip AD, Zonnenberg BA, and van Rijk PP: Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 33: 646-651, 1992.
8. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, Livingston RB, Gordon EE, Chapman R, and Appelbaum FR: Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 34: 1839-1844, 1993.
9. Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE, et al: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25: 805-813, 1993.
10. Geldof AA, and Rao BR: Prostatic tumor (R3327) skeletal metastasis. Prostate 16: 279-290, 1990.
11. Geldof AA, Rao BR, and de Voogt HJ: Direct effects of chemotherapeutic agents on rat prostate tumor clonogenic cells. Anticancer Res 6: 837-840, 1986.
12. Sun YC, Geldof AA, Newling DWW, and Rao BR: Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates. J Urol 148: 1270-1273, 1992.
13. Johnston RF, Pickett SC, and Barker DL: Autoradiography using storage-phosphor technology. Electrophoresis 11: 355-360, 1990.
14. de Klerk JMH, Zonnenberg BA, van het Schip AD, van Dijk A, Han SH, Quirijnen JM, Blijham GH, and van Rijk PP: Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med 21: 1114-1120, 1994.
15. de Klerk JMH, van Dieren EB, van het Schip AD, Hoekstra A, Zonnenberg BA, van Dijk A, Rutgers DH, Blijham GH, and van Rijk PP: Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. J Nucl Med 37: 38-41, 1996.
16. de Klerk JMH, van het Schip AD, Zonnenberg BA, van Dijk A, Quirijnen JMSP, Blijham GH, and van Rijk PP: Phase I study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. J Nucl Med 37: 244-249, 1996.
17. Mertens WC, Porter AT, Reid RH, and Powe JE: Strontium-89 and low dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. J Nucl Med 33: 1437-1443, 1992.